125 Participants Needed

Data Collection for VHL Syndrome

EJ
Overseen ByEric Jonasch, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to gather detailed information from individuals living with Von Hippel Lindau (vHL) disease, a genetic condition that can cause tumor growth in various parts of the body. Researchers seek to understand the current state of the disease, the treatments or surgeries patients have undergone, and the impact on their daily lives. Individuals who have been genetically diagnosed with vHL or meet the clinical criteria for it, and can provide informed consent, might be suitable candidates for this study. As an unphased trial, this study offers a unique opportunity to contribute to a deeper understanding of vHL and potentially improve future care strategies.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on gathering detailed data for patients with Von Hippel Lindau (VHL) disease, a condition that currently relies on surgical interventions and targeted therapies like sunitinib and sorafenib. This data collection protocol aims to provide a comprehensive understanding of the disease progression and the effectiveness of existing treatments in real-world settings. By analyzing this data, researchers hope to uncover new insights that could lead to more effective and personalized treatment strategies for VHL patients in the future.

Who Is on the Research Team?

EJ

Eric Jonasch, MD

Principal Investigator

ejonasch@mdanderson.org

Are You a Good Fit for This Trial?

Inclusion Criteria

Presence of genetic confirmation or clinical criteria consistent with vHL disease.
Ability to understand and the willingness to sign a written informed consent document.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Collection of prospective and retrospective data on lesion development, surgical history, and systemic therapy use in patients with vHL disease

Ongoing

Quality of Life Assessment

Obtain quality of life data in patients with vHL disease

Ongoing

Follow-up

Participants are monitored for safety and effectiveness after data collection

4 weeks

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+